Entecavir downregulates interleukin-37 in patients with chronic active hepatitis B infection-Reference-Cited by-同舟云学术

Entecavir downregulates interleukin-37 in patients with chronic active hepatitis B infection

Published:2020-01 Issue:1 Volume:48 Page:030006051988415
ISSN:0300-0605
Container-title:Journal of International Medical Research
language:en
Short-container-title:J Int Med Res

Author:

Meng Jiang-Ping¹,Luo Peng²,Bai Yao²,Cui Fang²^ORCID

Affiliation:

1. Assisted Reproductive Center, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

2. Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Publisher

SAGE Publications

Subject

Biochemistry, medical,Cell Biology,Biochemistry,General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/0300060519884157

Reference24 articles.

1. Treatment of chronic hepatitis B infection-2017

2. Present and future therapies of hepatitis B: From discovery to cure

3. Serum Interleukin-37 Concentrations and HBeAg Seroconversion in Chronic HBV Patients During Telbivudine Treatment

4. Introduction to the interleukin-1 family of cytokines and receptors: Drivers of innate inflammation and acquired immunity

5. Suppression of innate inflammation and immunity by interleukin-37

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correlation analysis of IL‐37 gene polymorphisms and susceptibility to chronic HBV infection among Han people in Central China;International Journal of Immunogenetics;2023-09-21

2. Osteoprotegerin and Interleukin-37 are Correlated with Liver Diseases in Chronic Hepatitis B Virus (HBV)-infected Subjects;The Indonesian Biomedical Journal;2023-06-26

3. Interleukin-37 suppresses the cytotoxicity of hepatitis B virus peptides-induced CD8+ T cells in patients with acute hepatitis B;Bosnian Journal of Basic Medical Sciences;2022-11-02

4. Statin use and risk of progression to liver cirrhosis in chronic hepatitis B independent of conventional risk factors: A nationwide study;Hepatology Communications;2022-06-29